Developing a new vaccine to prevent Salmonella infections
Synthetic glycan conjugates with bacteriophage Qbeta for broad spectrum anti-salmonella vaccines
This study is working on a new vaccine to help protect people from Salmonella infections by using special parts of the bacteria to boost the immune system, and it's aimed at anyone who wants better protection against this common health issue.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Michigan State University NIH-funded |
| Lab location | 1 site (East Lansing, United States) |
| Project ID | NIH-10653943 on NIH RePORTER |
What this research studies
This research focuses on creating a new type of vaccine to combat Salmonella infections, which are a significant global health issue. The approach involves synthesizing specific carbohydrate structures found on the surface of Salmonella bacteria and attaching them to a virus-like particle, bacteriophage Qβ, to enhance the immune response. The goal is to develop a broad-spectrum vaccine that can protect against multiple strains of Salmonella, potentially offering long-lasting immunity. Preliminary results have shown promising immune responses in animal models, indicating the potential effectiveness of this vaccine.
Who could benefit from this research
Good fit: Ideal candidates for this research would include individuals at high risk for Salmonella infections, such as those living in areas with high rates of salmonellosis or those with compromised immune systems.
Not a fit: Patients who are not at risk for Salmonella infections or those who have already been vaccinated against Salmonella may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a highly effective vaccine that significantly reduces the incidence of Salmonella infections worldwide.
How similar studies have performed: Other research has shown success with similar vaccine approaches using carbohydrate structures and virus-like particles, indicating a promising avenue for developing effective vaccines.
Where this research is happening
East Lansing, United States
- Michigan State University — East Lansing, United States (Active)
Researchers
- Principal investigator: Huang, Xuefei — Michigan State University
- Study coordinator: Huang, Xuefei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.